DTaP 접종력이 없는 3개월 미만 영아의 백일해 3례
Three Cases of Pertussis in Infants younger than Three Months without Immunization of DTaP
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
저자들은 발작적인 기침증상 및 간헐적으로 동반되는 구토, 청색증이 있는 신생아 및 3개월 미만의 유아에서 백일해균에 대한 배양검사와 PCR로 백일해를 확진하여 치료하였던 환자를 경험하였다. DTaP 접종이 완료되지 않은 신생아와 어린 영유아가 기침 증상이 오랫동안 지속되고 청색증, 호흡곤란이 동반된다면 백일해를 염두해 두어야 한다. 또한 청소년 및 성인에서 영유아로의 백일해 전파를 방지하며 집단 면역을 유지하기 위해 Tdap 백신의 접종을 적극적으로 권장해야 할 것이다.
Abstract
Pertussis is a pediatric infectious disease with one of the highest degrees of infectivity. Although pertussis may cause asymptomatic infections in children and adults with immunity, it can cause life-threatening diseases in newborn babies or infants. We report three cases of pertussis in infants ˂3 months of age without DTaP immunization who have received symptomatic treatment with the diagnosis of bronchiolitis from other hospitals, and subsequently correctly diagnosed and treated. The patients did not have the characteristic whooping cough, but the main symptoms were episodic cough, intermittent vomiting, and cyanosis. Based on culture results for Bordetella pertussis and PCR, pertussis was diagnosed and treated without any complications. As it is assumed that adults, adolescents, and asymptomatic patients may serve as sources of infection, immunization with Tdap vaccine is recommended to prevent dissemination of pertussis from adolescents and adults to infants, and thus maintain herd immunity.
참고문헌 (17)
- Cherry JD, "Pertussis and other Bordetella infections, in Feigin and Cherry’s textbook of pediatric infectious diseases. 6th ed", pp.1683~1706 (2009), Saunders Co
- Tan T, "Epidemiology of pertussis", Pediatr Infect Dis J, 24(Suppl 5), pp.10~18 (2005)
- 홍정연, "Update on pertussis and pertussis immunization", Korean Journal of Pediatrics, 53(5), pp.629~633 (2010), 대한소아과학회
- Department of Vaccines and Biologicals, "WHO-recommended standards for surveillance of selected vaccine -preventable diseases", pp.28~30 (2003), WHO
- Heininger U, "Serious pertussis overlooked in infants", Eur J Pediatr, 151, pp.342~343 (1992)
- Cherry JD, "Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives", Pediatr Infect Dis J, 24(Suppl 5), pp.25~34 (2005)
- 박완범, "성인의 만성 기침에 대한 감별진단으로서의 백일해", Infection and Chemotherapy, 36(6), pp.331~334 (2004), 대한감염학회
- Senzilet LD, "Pertussis is a frequent cause of prolonged cough illness in adults and adolescents", Clin Infect Dis, 32, pp.1691~1697 (2001)
- The Korean Pediatric Society, "DTaP, Td vaccination, in Immunization Guideline. 6th", pp.81~82 (2008), The Korean Pediatric Society
- Centers for Disease Control and Prevention, "Scheduled for persons aged 0 through 18 years", MMWR, 57, pp.51~52 (2009)
- Department of Vaccine and Biologicals, "World Health Organization. Pertussis surveillance: a global meeting Geneva", pp.28~30 (2001), WHO
- Tanaka M, "Trends in pertussis among infants in the United States, 1980- 1999", JAMA, 290, pp.2968~2975 (2003)
- Munoz FM, "Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention", Semin Pediatr Infect Dis, 17, pp.14~19 (2006)
- Akari Nakamura, "Neonatal pertussis presenting as acute bronchiolitis: direct detection of the Bordetella pertussis genome using loop-mediated isothermal amplification", Eur J Pediatr, 168, pp.347~349 (2009)
- Kamachi K, "Development and evaluation of a loop-mediated isothermal amplification method for rapid diagnosis of Bordetella pertussis infection", J Clin Microbiol, 44, pp.1899~1902 (2006)
- Langley JM, "Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis", Pediatrics, 114, pp.e96~e101 (2004)
- Hoppe JE, "In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides(HMR 3004 and HMR 3647), four macrolides(azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins(rifampicin and rifapentine)", Antimicrob Agents Chemother, 42, pp.965~966 (1998)